Síndrome SAPHO : Revisión clínica y radiológica

La síndrome SAPHO és una entitat clínica i radiològica que combina la sinovitis, l'acné, la pustulosis, la hiperostosis i la osteïtis. En aquesta sèrie es recullen les característiques clíniques de 52 malalts i es revisen les exploracions complementàries realitzades, principalment la gammagrafia òssia i la tomografia computada. Després d'analitzar les característiques radiològiques de la tomografia computada trobem un denominador comú: l'esclerosi, les erosions i la hiperostosi. La concordància amb els resultats d'altres sèries, recolze aquesta síndrome com una entitat ben definida clínica i radiològica.El Síndrome SAPHO es una entidad clínicoradiologica que combina sinovitis, acné, pustulosis, hiperostosis y osteítis. En esta serie se recogen las características clínicas de 52 pacientes y se revisan las exploraciones complementarias realizadas, principalmente la gammagrafía osea y la tomografía computarizada. Después de analizar las características radiológicas de la tomografía computarizada encontramos un denominador común: la esclerosis, las erosiones y la hiperostosis. La homogeneidad con los resultados de otras series da soporte a este síndrome como una entidad bien definida, clínica y radiológicamente

Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain

Dual targeted therapy (DTT) has emerged as a promising approach in patients with refractory spondyloarthritis (SpA) or psoriatic arthritis (PsA) and extra-musculoskeletal manifestations of both diseases, but its effectiveness/safety ratio still remains unclear. This is a retrospective, real-world multicenter study in refractory SpA and PsA patients with simultaneous use of two biological or synthetic targeted agents. Effectiveness was assessed using Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Disease Activity in Psoriatic Arthritis (DAPSA) Score. We identified 39 different DTT combinations in 36 patients (22 SpA; 14 PsA), 25 of them with concomitant inflammatory bowel disease. The most commonly used combinations were TNF inhibitor plus antagonist of the IL12/23 pathway, followed by TNF inhibitor plus IL-17 antagonist. During a median exposure of 14.86 months (IQR 8-20.2), DTT retention rate was 69.4% (n=25/36; 19 SpA, 6 PsA). Major clinical improvement (change in ASDAS-CRP > 2 or improvement > 85% in DAPSA) was achieved in 69.4% of patients (n=25/36 therapeutical combinations; 17/21 SpA, 8/15 PsA), with a 58.3% (n=21/36 combinations; 15/20 SpA, 6/13 PsA) low-activity/remission rate. Of the patients who were receiving glucocorticoids, 55% managed to withdraw them during follow-up. Interestingly, only four serious adverse events in three patients were observed, leading to DTT discontinuation

The incidence of clinical fractures in adults aged 50 years and older in Spain

Objective. The aim of this study was to quantify the incidence of all clinical fractures, including traumatic and fragility fractures, in patients aged 50 years and older, and to describe their distribution by fracture location, sex and age. Methods. The incidence of clinical fractures at 10 hospitals in Catalonia, with a reference population of 3 155 000 inhabitants, was studied. For 1 week, from 30 May to 5 June 2016, we reviewed the discharge reports of the Traumatology section of the Emergency Department to identify all fractures diagnosed in patients ≥50 years of age. As a validation technique, data collection was carried out for 1 year at one of the centres, from 1 December 2015 to 30 November 2016. The fracture incidence, including the 95% CI, was estimated for the entire sample and grouped by fracture type, location, sex and age. Results. A total of 283 fractures were identified. Seventy per cent were in women, with a mean age of 72 years. The overall fracture incidence was 11.28 per 1000 person-years (95% CI: 11.10, 11.46), with an incidence of traumatic and fragility fractures of 4.15 (95% CI: 4.04, 4.26) and 7.13 per 1000 person-years (95% CI: 6.99, 7.28), respectively. The incidence of fractures observed in the validation sample coincided with that estimated for the whole of Catalonia. The most common fragility fractures were of the hip, forearm, humerus and vertebrae. Conclusion. The results of this study are the first to estimate the incidence of clinical fragility fractures in Spain, grouped by location, age and sex

Síndrome SAPHO: Revisión clínica y radiológica

La síndrome SAPHO és una entitat clínica i radiològica que combina la sinovitis, l’acné, la pustulosis, la hiperostosis i la osteïtis. En aquesta sèrie es recullen les característiques clíniques de 52 malalts i es revisen les exploracions complementàries realitzades, principalment la gammagrafia òssia i la tomografia computada. Després d’analitzar les característiques radiològiques de la tomografia computada trobem un denominador comú: l’esclerosi, les erosions i la hiperostosi. La concordància amb els resultats d’altres sèries, recolze aquesta síndrome com una entitat ben definida clínica i radiològica.El Síndrome SAPHO es una entidad clínicoradiologica que combina sinovitis, acné, pustulosis, hiperostosis y osteítis. En esta serie se recogen las características clínicas de 52 pacientes y se revisan las exploraciones complementarias realizadas, principalmente la gammagrafía osea y la tomografía computarizada. Después de analizar las características radiológicas de la tomografía computarizada encontramos un denominador común: la esclerosis, las erosiones y la hiperostosis. La homogeneidad con los resultados de otras series da soporte a este síndrome como una entidad bien definida, clínica y radiológicamente